Indivior Pharmaceuticals (INDV) Non-Current Debt (2021 - 2026)

Indivior Pharmaceuticals has reported Non-Current Debt for 6 years, with the latest figure at $487.0 million in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 58.12% year-over-year to $487.0 million in Q2 2026; TTM through Jun 2026 was $487.0 million, a 58.12% increase from a year earlier, with the FY2025 full-year figure at $290.0 million, down 7.94% from the prior year.
• Non-Current Debt was $487.0 million for Q2 2026 at Indivior Pharmaceuticals, roughly flat from $486.0 million in the prior quarter.
• The five-year high for Non-Current Debt was $487.0 million in Q2 2026, with the low at $237.0 million in Q4 2022.
• Average Non-Current Debt over 5 years is $330.6 million, with a median of $308.0 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt decreased 7.94% in 2025, then jumped 58.12% in 2026.
• Over 5 years, Non-Current Debt stood at $237.0 million in 2022, then changed by 0.0% to $237.0 million in 2023, then jumped by 32.91% to $315.0 million in 2024, then fell by 7.94% to $290.0 million in 2025, then soared by 67.93% to $487.0 million in 2026.
• The last three Non-Current Debt figures came in at $487.0 million (Q2 2026), $486.0 million (Q1 2026), and $290.0 million (Q4 2025), per Business Quant data.